According to study, “Middle East and Africa Precision
Medicine Market (2018-2023)” some of the major
companies that are currently working in the Middle East and Africa precision
medicine market are Johnson & Johnson, Biocrates Life Sciences, Abbott
Laboratories, Randox Laboratories, GlaxoSmithKline (GSK), Ferrer InCode,
Intomics, GE Healthcare, Covance Ltd., Novartis AG, Quest Diagnostics, Pfizer, Silicon
Biosystems, Teva Pharmaceuticals Limited, Nanostring Technologies, Medtronic, CETICS
Healthcare Technologies GmbH, Eagle Genomics, Qiagen Technologies, Tepnel Pharma
Services, Almac Group. Additionally, some ecosystem players are healthcare
information technology specialists or big data companies, clinical
laboratories, pharmaceuticals & biotech companies and diagnostic companies
etc.
Precision medicine helps incurring
patient’s genetic existence, and atmosphere. Its main objective is to provide
the accurate treatments to the patients at the exact time. It helps in building
a scientific knowledge support by raising a network of technical group study. It
also helps doctors and researchers to apply the protective methods for any precise
sickness. It treats many cancer cells for instance HER2-positive breast cancer
cells, or using tumor indicator testing to facilitate diagnose cancer. All
these medicines are issued by the Food and Drug Administration or FDA. Some of
the essential features of precision market include protective care, limit cost,
the competence of care and inhabitants health and many others. Additionally,
some of the side effects are bruising, appetite loss, bleeding, anemia, delirium,
diarrhea, fatigue, alopecia, neutropenia, infection, nausea, constipation,
edema, memory loss vomiting and nerve problem and many others.
Based on the therapeutics, the
precision market is segmented into central nervous system, cardiovascular,
psychiatric disorder, cancer and virus diseases etc. Based on technology market
is segmented into companion diagnostics, bioinformatics, pharmacogenomics,
genetic material sequencing and big data analytics. Moreover based on the
application market is segmented into oncology, CNS, respiratory and immunology
etc.
The Middle East and Africa
precision medicine are driven by increasing technological advancements, rising prevalence
diseases (malaria, HIV, tuberculosis etc), increasing global incidence of
cancer, rising the adoption of IoMT and healthcare technologies, huge
population and supportive government initiatives etc. Apart from advantages,
some of the major challenges are lack of adequately trained healthcare workers,
poor economic condition and lack of training programs and many others.
Moreover, some of the other drawbacks hampering are infrastructure
requirements, legal problems, healthcare cost and the relevance of the
information and many others.
The National Human Genome Research
Institute (NHGRI) is human genome project, which is part of the National
Institutes of Health (NIH). It supports investigation of the complex legal, ethical
and social inferences of genomics and also provides the knowledge &
benefits of genomics research. In addition, the Human Heredity and Health in
Africa (H3Africa) is a government initiative. The main goal of initiative is to
support African scientists, which use clinical, genomic and epidemiologic
methods to identify genetic and ecological offerings to the risk of common,
non-communicable disorders (such as kidney and heart disease) and communicable
diseases (tuberculosis).
It is estimated that the Middle
East and Africa precision medicine market to reach at USD 2.5 billion, at a
CAGR of 9.9%, by 2023. In upcoming years, it is expected that market to grow
increasingly due to increasing demand for personalized treatment and rising in
cancer susceptible aging population.
To know more, click on the link
below:
Related Reports :
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
